News
12-14-2009, 01:32 AM
Pfizer Inc. today announced results from studies evaluating neratinib (HKI-272), an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 (HER2, also known as ErbB2) positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).
More... (http://www.news-medical.net/news/20091214/Pfizer-announces-results-from-studies-evaluating-neratinib.aspx)
More... (http://www.news-medical.net/news/20091214/Pfizer-announces-results-from-studies-evaluating-neratinib.aspx)